aripiprazole / Generic mfg. - LARVOL DELTA

Clinical trial to study the effect of an already authorized drug on othernpathologies by administering it to people with a recent diagnosis ofnschizophrenia. (clinicaltrialsregister.eu) - P2/3 | N=37 | Recruiting | Sponsor: Fundacion Para La Gestion De La Investigacion En Salud De Sevilla | Not yet recruiting ➔ Recruiting

Enrollment open • CNS Disorders • Psychiatry • Schizophrenia

Female Sexual Dysfunction Induced by Second-Generation Antipsychotic Drugs-A Disproportionality Analysis Based on the FAERS Database. (PubMed, Schizophr Bull) - "This pharmacovigilance study highlights significant associations between specific SGAs and female sexual dysfunction. Disproportionality signals vary by drug, symptom type, and prolactin-related mechanisms. Clinicians should consider sexual side effects in treatment decisions and monitor patients accordingly. Further prospective studies are warranted."

Journal • CNS Disorders • Mental Retardation • Psychiatry • Sexual Disorders

The Impact of Sex and Age on Antipsychotic Serum Concentrations. (PubMed, Schizophr Bull) - "We found sex differences in olanzapine and clozapine concentrations, which were most pronounced until 45 years of age. Our findings suggest that monitoring antipsychotic levels may add clinical value and underscore the need for sex-specific prescription guidelines for olanzapine and clozapine."

Journal • CNS Disorders • Psychiatry

In Vitro/In vivo evaluation of aripiprazole long-acting injectable microsuspension and development of IVIVC. (PubMed, Int J Pharm) - "Pharmacokinetic profiles of several formulations were evaluated in a rat model, and in vitro dissolution data were obtained using the flow-through method were evaluated in relation to in vivo performance to explore potential in vitro-in vivo correlations. The results indicate that the resulting model is capable of reasonably capturing burst-release behavior associated with differences in particle size and morphology, supporting formulation and process optimization."

Journal • Preclinical

Co-Administration Treatment in Drug-Naïve Major Depression: Exploratory Real-World Patterns and Predictors in China. (PubMed, Neuropsychiatr Dis Treat) - "The most prescribed adjunctive antidepressants were SNRIs, NaSSAs, bupropion, and trazodone; the most common antipsychotics were quetiapine, olanzapine, aripiprazole, and risperidone...This practice appears to be a symptom-driven approach, targeting specific features like sympathetic arousal and leaden paralysis, which may reflect a pragmatic adaptation to local clinical realities beyond standard guidelines. Due to exploratory nature of the study, these findings are just hypothesis-generating, warranting further validation through more robust, longitudinal studies."

Journal • Real-world evidence • CNS Disorders • Depression • Major Depressive Disorder • Mood Disorders • Psychiatry

The importance of central sensitization management in prosthodontic clinical practice: Two case reports of phantom bite syndrome. (PubMed, J Prosthodont Res) - "Maintaining pharmacotherapy throughout prosthetic treatment stabilized PBS symptoms, reduced relapse risk, and improved acceptance of definitive restorations. Recognition of possible central nervous system involvement, even without overt psychiatric comorbidity, broadens therapeutic options and supports better outcomes. Future studies should expand clinical case data, refine medication strategies, define optimal treatment timing, and strengthen interdisciplinary collaboration in PBS management."

Journal • Immunology • Psychiatry

Cognitive behavioral therapy combined with aripiprazole in the treatment of schizophrenia: effects on cognitive function and psychological state. (PubMed, Front Psychiatry) - "Subgroup analysis showed better treatment responses in younger patients and those with a shorter disease duration. CBT combined with aripiprazole significantly improves the psychiatric symptoms, cognitive function, and emotional state of patients with schizophrenia, and the frequency and intensity of treatment have a positive impact on efficacy."

Journal • CNS Disorders • Depression • General Anxiety Disorder • Mood Disorders • Psychiatry • Schizophrenia

CINEMA: Cerebellum-based Imaging Neural Markers for Antipsychotic Response (clinicaltrials.gov) - P=N/A | N=120 | Recruiting | Sponsor: Northwell Health

New trial • CNS Disorders • Psychiatry

Chemoprevention of hepatocellular carcinoma by next-generation antipsychotic aripiprazole (EASL 2026) - No abstract available

CNS Disorders • Hepatocellular Cancer • Oncology • Solid Tumor

Chemoprevention of hepatocellular carcinoma by next-generation antipsychotic aripiprazole. (PubMed, Hepatology) - "Finally, treatment of patient-derived tumorspheroids demonstrated that aripiprazole modulates immune responses in the tumor microenvironment. Collectively, these findings suggest that treatment with aripiprazole is a clinically relevant approach for HCC chemoprevention."

Journal • CNS Disorders • Fibrosis • Hepatocellular Cancer • Hepatology • Immunology • Liver Cancer • Liver Cirrhosis • Metabolic Dysfunction-Associated Steatohepatitis • Oncology • Solid Tumor

Psychotropic drug-induced obesity in older adults: complications, preventive and therapeutic interventions (PubMed, Orv Hetil) - "Among psychotropic drugs, olanzapine, clozapine, quetiapine, mirtazapine, valproate, and lithium are associated with the most significant weight gain through complex mechanisms (H1 blockade, 5-HT2C antagonism, metabolic effects); however, other antipsychotics, mood stabilizers, and antidepressants may also contribute to weight increase...Prevention hinges on preferring agents with lower metabolic risk (e.g., aripiprazole, venlafaxine, lamotrigine), regular monitoring, and proactive lifestyle interventions. Therapeutically, switching medications, intensive lifestyle programs, metformin, or GLP1 agonists may be employed...Orv Hetil. 2026; 167(11): 410-418."

Journal • Review • Cardiovascular • CNS Disorders • Diabetes • Genetic Disorders • Geriatric Disorders • Metabolic Disorders • Obesity • Oncology • Sarcopenia

Effect of anticancer activity of aripiprazole main metabolite OPC-14857 on malignant glioblastoma. (PubMed, PLoS One) - "Both demonstrated more potent anticancer activity than temozolomide, the current standard clinical therapy for malignant glioblastoma...ARP and OPC enhanced doxorubicin (DOX) efficacy, likely via P-glycoprotein inhibition; known for ARP, suggested for structurally similar OPC...Although our observations were limited to in vitro studies, our findings suggest that OPC may have sustained anticancer effects even when ARP is metabolized in humans. Therefore, if ARP can be used for drug repurposing in glioblastoma, the long-term effects of OPC could be anticipated."

Journal • Brain Cancer • CNS Disorders • Glioblastoma • Oncology • Solid Tumor • BIRC5

A Retrospective Study of Mood and Anxiety Disorders Management Profile (MooD-MaP) of Patients Admitted at the Makati Medical Center from 2014-2017. (PubMed, Psychopharmacol Bull) - "In MDD, clonazepam, escitalopram, quetiapine, and aripiprazole predominated, while clonazepam and selective serotonin reuptake inhibitors were most commonly used in AD. Psychopharmacologic management of hospitalized patients with mood and anxiety disorders in this Philippine tertiary center largely aligns with international practice. High rates of polypharmacy and suicidality underscore the need for optimized, evidence-based prescribing and longitudinal outcome studies."

Journal • Retrospective data • Bipolar Disorder • CNS Disorders • Depression • Major Depressive Disorder • Mood Disorders • Psychiatry

Clozapine After 1 Failed Antipsychotic Drug Trial in First-Episode Psychosis: A Randomized Clinical Trial. (PubMed, JAMA Psychiatry) - P3 | "In phase 1, patients with FEP were randomized to receive oral olanzapine, risperidone, amisulpride, aripiprazole, or perphenazine for 8 weeks. This study provides some evidence for clinicians to consider regarding use of clozapine as the next sequential treatment after patients have failed an adequate trial with 1 of the more traditional antipsychotics. ClinicalTrials.gov Identifier: NCT03510325."

Clinical • Journal • CNS Disorders • Psychiatry • Schizophrenia • Schizophreniform Disorder

MEDICAID DRUG REBATE AND SAVINGS IMPLICATIONS OF MOST FAVORED NATION PRICING UNDER THE GENEROUS MEDICAID MODEL (ISPOR 2026) - "At product level, the largest price reductions were observed for Vraylar (79.8%), Ozempic (69.19%), and Entresto (62.44%). The largest contributors to aggregate Medicaid savings were Abilify (910 million), Ozempic (377 million), and Trikafta (292 million). MFN reference pricing under Medicaid GENEROUS model would reduce Medicaid spending for some, but not all, high-cost drugs. Estimated savings are highly sensitive to the choice of reference price benchmark, highlighting the importance of benchmark design in any future implementation of international reference pricing."

Medicaid • Pricing • Reimbursement • US reimbursement

COMPARATIVE EFFICACY AND SAFETY OF LUMATEPERONE AND OTHER ATYPICAL ANTIPSYCHOTICS APPROVED AS ADJUNCTIVE THERAPY FOR MAJOR DEPRESSIVE DISORDER: A NETWORK META-ANALYSIS (ISPOR 2026) - "This network meta-analysis (NMA) compared efficacy and safety of lumateperone with other approved atypical antipsychotics: aripiprazole, brexpiprazole, cariprazine, and quetiapine XR for MDD with inadequate response to antidepressants (ADT). Ten short-term, randomized, double-blind, placebo-controlled registration trials formed a star-shaped network of 11 treatment- and dose-specific nodes anchored on placebo+ADT. In this NMA, lumateperone demonstrated a favorable efficacy profile versus other approved adjunctive antipsychotics, with no increased risk of weight gain. Balancing efficacy and safety is crucial when selecting adjunctive antipsychotic treatment for MDD."

Retrospective data • CNS Disorders • Depression • Major Depressive Disorder • Mood Disorders • Psychiatry

CESAR: Comparison of esketamine with an antidepressant versus aripiprazole with an antidepressant, in the refractory major depression disorder in elderly patients (clinicaltrialsregister.eu) - P2/3 | N=220 | Recruiting | Sponsor: Fundacion Publica Andaluza Para La Gestion De La Investigacion En Salud De Sevilla | Not yet recruiting ➔ Recruiting

Enrollment open • CNS Disorders • Depression • Geriatric Disorders • Major Depressive Disorder • Mood Disorders • Psychiatry

Beyond genetics: A rare case of childhood disintegrative disorder following psychosocial trauma. (PubMed, J Pediatr Nurs) - "This case highlights severe psychosocial trauma acting as a critical trigger for the onset of CDD. It emphasizes the need for pediatric nurses to recognize trauma-related regression, integrate trauma-informed care, and coordinate family assessment and support."

Journal • Autism Spectrum Disorder • CNS Disorders • Genetic Disorders • Mood Disorders • Pediatrics • Psychiatry • Sleep Disorder

Antipsychotics in Children and Adolescents with Schizophrenia-Spectrum Disorders: A Systematic Review, Meta-Analysis, and Long-Term Prospective Evidence. (PubMed, J Child Adolesc Psychopharmacol) - "Several SGAs produce short-term symptom reductions versus placebo in children and adolescents with schizophrenia-spectrum disorders, with heterogeneity in TEAE risk across agents. Evidence for long-term maintenance and continuation remains limited, underscoring the need for adequately powered randomized continuation trials to guide sustained treatment in this population."

Journal • Retrospective data • Review • CNS Disorders • Mental Retardation • Psychiatry • Schizophrenia

Antipsychotic Aripiprazole affects the sexual behavior and biochemical parameters of female Wistar rats. (PubMed, Reprod Toxicol) - "Biochemical changes in creatinine, albumin, and triglycerides were observed, in addition to adverse effects on cyclicity and sexual behavior. Thus, aripiprazole at doses of 0.3 and 6.0mg/kg in this experimental model may cause toxic effects on the endocrine-reproductive system of fertile rats."

Journal • Preclinical • CNS Disorders • Mental Retardation • Psychiatry • Schizophrenia

Comparison of Antipsychotics in the Treatment of COVID-19-Induced First-Episode Psychosis: A Review of Case Studies. (PubMed, Cureus) - "Olanzapine was the most commonly used single antipsychotic (6, 28.6%), while the combination of haloperidol and aripiprazole was the most frequently used antipsychotic regimen (4, 19.0%). Reported side effects included fatigue, weight gain, akathisia, leukocytosis, and QT-interval prolongation (5, 11.9%), with a relapse rate of (2, 4.8%). This review evaluates the treatment methods for COVID-19 FEP and develops a deeper understanding of various antipsychotics used in managing psychosis and its outcomes."

Journal • Review • CNS Disorders • Fatigue • Infectious Disease • Novel Coronavirus Disease • Psychiatry • Respiratory Diseases

Clinical Practice Guideline on the Choice of First Antipsychotic Medicine for Females Experiencing a First-Episode of Psychosis. (PubMed, Schizophr Bull) - "This is the first CPG addressing antipsychotic choice for females with FEP. By prioritizing critically important patient outcomes and lived experience, the guideline supports safer, sex-sensitive prescribing for females that may improve treatment acceptability, adherence, and equity in psychosis care."

Clinical guideline • Journal • CNS Disorders • Psychiatry

Reversible aripiprazole-induced tardive dyskinesia: a case series from Saudi Arabia and literature review. (PubMed, Front Psychiatry) - "In this case series, we discuss three cases involving Saudi women who developed aripiprazole-induced TD; notably, all cases remitted upon aripiprazole discontinuation or dose reduction without utilizing other forms of treatment. The current literature remains limited in describing aripiprazole-induced TD, lacking a clear understanding of the development of TD following aripiprazole administration, the determined remission rate, and definite management."

Journal • CNS Disorders • Movement Disorders

A Genetic Triple Play: Adolescent-onset Hyperkinetic Syndrome with Multilocus KMT2B and FGF14 Variants and Familial Hunter Syndrome in One Pedigree (AAN 2026) - "Symptomatic treatment with aripiprazole improved choreiform movements, and botulinum toxin injections were effective for cervical dystonia... This case broadens the phenotypic spectrum of KMT2B-related dystonia by highlighting the presence of choreiform movements - a feature reported in only ~2% of cases. The co-occurrence of an FGF14 repeat expansion and familial Hunter syndrome in the same pedigree illustrates the impact of three distinct genetic mechanisms: epigenetic dysregulation (KMT2B), ion channel dysfunction (FGF14), and lysosomal storage pathology (Hunter syndrome). Together, they exemplify how diverse molecular pathways can converge to produce complex neurological phenotypes within a single family."

ADHD (Impulsive Aggression) • Ataxia • CNS Disorders • Dystonia • Hunter Syndrome • Huntington's Disease • Movement Disorders • KMT2B

Two Cases of Chorea-acanthocytosis (VPS13A Disease) (AAN 2026) - "He experienced severe leg pain, which improved alongside psychosis and dyskinesias with low-dose aripiprazole...Treatment with riluzole helped stabilize symptoms six years after onset... These cases reinforce the clinical heterogeneity of chorea-acanthocytosis, which can mimic Huntington disease. While no cure exists, early recognition can guide supportive care and counseling. The pathophysiology involves impaired protein trafficking due to chorein deficiency, highlighting potential therapeutic targets."

Clinical • Amyotrophic Lateral Sclerosis • Cardiovascular • CNS Disorders • Dystonia • Epilepsy • Gastrointestinal Disorder • Genetic Disorders • Huntington's Disease • Movement Disorders • Parkinson's Disease • Peripheral Neuropathic Pain